Enfortumab vedotin in combination with pembrolizumab shows improved survival rates in la/mUC

Prof Thomas Powles speaks to ecancer about EV-302: an updated analysis from the phase 3 global study of enfortumab vedotin in combination with pembrolizumab compared to chemotherapy in previously untreated locally advanced or metastatic urothelial carcinoma (la/mUC). This study shows that the combination of enfortumab vedotin and pembrolizumab offers better response rates than traditional chemotherapy for metastatic bladder cancer. With a median follow-up of two and a half years, about 30% of patients achieve a complete response, indicating improved survival rates. Future research aims to enhance cure rates and explore bladder-sparing strategies.